{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.2","upperLimit":"34.8","value":"29.5"},{"groupId":"OG001","lowerLimit":"27.4","upperLimit":"38.8","value":"33.1"}]}],"title":"PFS at 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.0","upperLimit":"29.1","value":"24.1"},{"groupId":"OG001","lowerLimit":"21.0","upperLimit":"32.1","value":"26.6"}]}],"title":"PFS at 36 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.0","upperLimit":"24.6","value":"19.8"},{"groupId":"OG001","lowerLimit":"15.1","upperLimit":"25.9","value":"20.5"}]}],"title":"PFS at 48 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.3","upperLimit":"21.5","value":"16.9"},{"groupId":"OG001","lowerLimit":"10.5","upperLimit":"21.2","value":"15.9"}]}],"title":"PFS at 60 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.5","upperLimit":"49.0","value":"43.3"},{"groupId":"OG001","lowerLimit":"42.9","upperLimit":"54.5","value":"48.7"}]}],"title":"OS at 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.4","upperLimit":"42.8","value":"37.1"},{"groupId":"OG001","lowerLimit":"36.6","upperLimit":"48.3","value":"42.5"}]}],"title":"OS at 36 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.1","upperLimit":"38.3","value":"32.7"},{"groupId":"OG001","lowerLimit":"32.4","upperLimit":"44.0","value":"38.2"}]}],"title":"OS at 48 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.4","upperLimit":"34.3","value":"28.8"},{"groupId":"OG001","lowerLimit":"30.3","upperLimit":"41.8","value":"36.1"}]}],"title":"OS at 60 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"PFS was defined as time from randomization until any of the following: Progression of disease (per investigator), or death. For those with blast phase CML or Ph+ ALL, disease progression was: loss of OHR; no decrease from on-study baseline percent blasts in PB or BM on all assessments over a 4-week period after starting maximum dose; absolute increase of at least 50% in PB blast count over a 2-week period after starting maximum dose. For those with accelerated phase CML: the list above also included: Development of blast phase CML at any time after initiation of therapy and development of extra-medullary sites other than spleen or liver. Participants who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. OS was defined as time from randomization until date of death. Participants who had not died or were lost to follow-up were censored on the last date they were known to be alive. Median duration was measured in months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"Participants were analyzed based on the treatment they were randomized to receive. Kaplan-Meir estimates of PFS or OS (95% Confidence Interval) are provided below.","reportingStatus":"POSTED","timeFrame":"24 months, 36 months, 48 months, 60 months","title":"Progression Free Survival (PFS) and Overall Survival (OS) at 24, 36, 48, and 60 Months - Randomized Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}